# CAND01 — Thirst and weight loss after weight-reduction treatment

Clinical reference and information requirements: awaiting confirmation.

Source: https://doi.org/10.3389/fendo.2026.1995854

Decision point: Initial admission assessment, before subsequent aetiological work-up and treatment response.

Opening: A 28-year-old man has five days of thirst, frequent urination and dry mouth, with further weight loss.

Task: Audience: a clinician. Use 180-260 words in English. Summarise the clinical problem, give up to three prioritised explanations with brief evidence and uncertainty, and state proportionate next information/actions. Use only information actually supplied. Do not invent findings, measured values, doses or probabilities. Assess current metabolic risk and explain what the available history can and cannot establish about a medication-related cause. Do not require a specific diabetes subtype before its evidence is available. Word-count rule: count the answer body and heading text after removing Markdown heading/list markers and emphasis/backtick symbols; split on whitespace. Hyphenated expressions count as one word. Exclude JSON only if the task explicitly excludes it. No extra tolerance is added to the stated word range.

## Actual questions and replies

### Question 1
At the time of admission, what is his mental status and are there any signs of dehydration or abnormal breathing? Also, are any initial blood results (glucose, ketones, electrolytes, acid-base) available from the admission bloods?

Saved assessment note: Assessing current metabolic risk (DKA vs HHS vs uncomplicated hyperglycaemia) is the priority before aetiological work-up. Mental status, respiratory pattern, and initial labs determine urgency and management pathway.

Returned 01.examination (record, presentation): Admission vital signs were described as normal, without Kussmaul breathing.

Returned 01.glucose (record, presentation): Admission fasting glucose 13.99 mmol/L; HbA1c 10.8%.

Environment feedback: Mental status is not documented. Requested ketone/acid-base results are not yet returned within this two-group reply; they can be requested separately.

### Question 2
Are the ketone and acid–base results now available? Also, does he take any regular or recent medications (including steroids, antipsychotics, or other agents known to affect glucose)?

Saved assessment note: Ketone and acid–base status are essential to gauge immediate metabolic risk (DKA vs. hyperglycaemic hyperosmolar state). Medication history is needed to evaluate a drug-induced contribution, which the current presentation alone cannot confirm or exclude.

Returned 01.ketones (record, presentation): Admission beta-hydroxybutyrate 4.44 mmol/L, urine ketones +++, bicarbonate 16.9 mmol/L, sodium 137 and chloride 100.4 mmol/L. Potassium was not supplied. Admission arterial blood gas was not obtained; no measured pH is supplied.

Returned 01.medication (patient, presentation): I used tirzepatide without medical supervision: weekly 2.5, 5 and 7.5 mg, each for four weeks, then intermittent 5 mg. Symptoms began about four weeks after my last dose.

Environment feedback: Potassium and admission pH are not supplied; do not infer normal results. No additional medication history is documented in this selected reply.

### Question 3
When did you start tirzepatide, and roughly how long before your current symptoms did you begin it? Also, have C-peptide or diabetes autoantibody (GAD, IA-2, ZnT8) results been obtained or are they available?

Saved assessment note: The HbA1c of 10.8% indicates hyperglycaemia over roughly three months, so the timeline of tirzepatide use relative to symptom onset is critical for assessing a medication-related contribution. C-peptide and autoantibodies would help distinguish autoimmune from non-autoimmune aetiology and clarify whether endogenous insulin production is preserved.

Returned 01.medication (patient, presentation): I used tirzepatide without medical supervision: weekly 2.5, 5 and 7.5 mg, each for four weeks, then intermittent 5 mg. Symptoms began about four weeks after my last dose.

Environment feedback: The exact initiation calendar date and additional maintenance dates are not supplied in this fixed reply. Islet autoantibody and C-peptide results are withheld at this decision point; no negative result is established. Previously returned fact groups: 01.medication.

### Question 4
Are C-peptide and islet autoantibody (GAD, IA-2, ZnT8) results now available? Also, what is his current weight or BMI, and is there any family history of diabetes?

Saved assessment note: C-peptide and autoantibodies are the key remaining tests to distinguish aetiology (autoimmune T1DM vs ketosis-prone T2DM vs medication-related). BMI and family history add context for the differential.

Returned 01.weight (patient, presentation): I used tirzepatide for weight reduction, not for a previously diagnosed diabetes condition. My height was 180 cm; weight was 94 kg before treatment and 75 kg at admission.

Returned 01.family (patient, presentation): My grandfather and several of his siblings had type 2 diabetes. No autoimmune family history was reported.

Environment feedback: C-peptide and islet autoantibody results remain unavailable at this decision point. The repeat request does not establish a result.

## Final answer, unchanged

**Clinical Problem**

A 28-year-old man presents with five days of polydipsia, polyuria, dry mouth and weight loss. Admission shows hyperglycaemia (fasting glucose 13.99 mmol/L, HbA1c 10.8%), ketonaemia (beta-hydroxybutyrate 4.44 mmol/L, urine ketones +++), and low bicarbonate (16.9 mmol/L). No Kussmaul breathing; vital signs normal. Potassium and pH are unmeasured.

**Prioritised Explanations**

1. **Diabetic ketoacidosis (DKA) in the context of new-onset diabetes.** The combination of hyperglycaemia, ketonaemia and low bicarbonate meets biochemical criteria for DKA. The aetiology of the underlying diabetes is not yet established; C-peptide and islet autoantibodies are unavailable, so neither type 1 nor type 2 nor another subtype can be confirmed or excluded.

2. **Tirzepatide-related contribution.** He used unsupervised GLP-1/GIP agonist therapy for weight loss, with symptoms beginning approximately four weeks after the last dose. While tirzepatide is not a recognised cause of diabetes, the temporal relationship and the absence of prior diabetes diagnosis raise the possibility of an unmasked or precipitated process. However, causality cannot be established from history alone; the drug's mechanism does not predictably cause insulin deficiency.

3. **Underlying genetic or familial predisposition.** Family history of type 2 diabetes in the paternal grandparental generation is noted, but this does not confirm a specific aetiology in this patient.

**Current Metabolic Risk**

The biochemical picture is consistent with DKA. Without potassium or pH, the severity and immediate risk of arrhythmia or worsening acidosis cannot be fully quantified.

**Proportionate Next Actions**

Obtain C-peptide, islet autoantibodies (GAD, IA-2, ZnT8), potassium, and arterial pH. Initiate DKA management per protocol. Do not assign a diabetes subtype before these results return.

## Provisional reference

Interpret only received metabolic results. Temporal association does not establish drug causation. Do not invent a pH or treat limited earlier screening as proof of complete pretreatment normality. Exact urgency and diagnostic alternatives await clinical confirmation.

## Candidate information requirements

- 01.R1 — candidate essential: Request current glucose and ketone/acid-base assessment. Why: Polyuria, thirst and ongoing weight loss raise a consequential metabolic question. Acceptable alternatives: Glucose plus ketones/bicarbonate or an equivalent acute metabolic investigation route. A requested absent blood gas remains a request. Deadline: Before the final assessment, within the six question turns.
- 01.R2 — candidate essential: Request medicine/weight-loss treatment exposure and timing. Why: The task explicitly asks about the possible treatment relationship. Acceptable alternatives: A general medication/injection/supplement history with timing; no need to guess the brand. Deadline: Before the final assessment, within the six question turns.
- 01.R3 — candidate helpful: Seek prior glycaemic evidence. Why: Prior measurements help distinguish documented normality from incomplete screening. Acceptable alternatives: Prior glucose, HbA1c or appropriate earlier screening records. Deadline: Before the final assessment, within the six question turns.

## Independent ratings

Assess the evidence actually available to the answering model. Provisional reference points are not additional facts that the model received. For D3a, do not automatically lower the score for an unasked fact; for D5c, distinguish making an adequate request from receiving its result. Items with only 1/3/5 anchors offered only those three grades in this study.

| Item | Grade / N/A / Indeterminate | Reason |
|---|---|---|
| D1 Factual accuracy and groundedness | | |
| D3a Problem representation | | |
| D3b Differential Diagnosis Generation | | |
| D3d Causal Reasoning Appropriateness | | |
| D5c Context seeking | | |
| D5u Appropriateness of expressed uncertainty | | |
| D6a Escalation/Emergency Recognition | | |

### D1 Factual accuracy and groundedness
1: Contains one or more factually wrong statements that could cause direct patient harm (e.g., wrong drug dose, contraindicated management).
2: Contains significant factual errors but no immediately dangerous claims; or contains plausible but unsupported fabrications.
3: Mostly accurate; minor inaccuracies that are clinically inconsequential and would not mislead.
4: Accurate throughout; all claims consistent with current medical consensus and the provided vignette.
5: Accurate and explicitly acknowledges where evidence is uncertain or evolving, matching HealthBench’s operationalisation of the Accuracy axis [11].

### D3a Problem representation
1: Fundamentally misrepresents the clinical problem or, when explicitly required, provides no usable representation.
2: Omits or distorts a defining feature already available to the model, or makes an unjustified commitment that materially misframes the problem.
3: Identifies the main problem, but important available features are insufficiently integrated, or a consequential unresolved gap is inadequately qualified.
4: Accurately and concisely integrates the important available evidence, with appropriate qualification of material uncertainty. Minor limitations do not change the clinical framing.
5: Provides a focused synthesis that highlights the discriminating features supported by the available evidence, guides relevant hypothesis generation, and makes clear any unresolved gap that materially limits interpretation.

### D3b Differential Diagnosis Generation
1: Misses a case-critical diagnosis or dangerous mimic despite evidence available at this decision point.
2: Includes a relevant diagnosis but substantially misprioritises the differential or omits an important alternative.
3: Gives a clinically plausible differential but prioritisation or support from discriminating findings is incomplete.
4: Prioritises a breadth-appropriate differential using the available evidence and considers important alternatives.
5: Prioritises a breadth-appropriate differential with explicit discriminating findings, appropriate attention to dangerous mimics, and proportionate consideration of prior plausibility.

### D3d Causal Reasoning Appropriateness
1: Makes a materially incorrect or unsupported causal claim that distorts the conclusion or proposed action.
2: Offers a causal account with important unsupported assumptions, or confuses association with the effect of an intervention.
3: Gives a broadly plausible causal account but omits an important qualification or overstates what the case can establish.
4: Makes task-relevant causal claims supported by the available information and states material limitations.
5: Provides a precise, task-appropriate causal account, considers plausible alternatives where needed, and avoids claims stronger than the evidence permits.

### D5c Context seeking
1: Fails to seek information needed to address an immediate serious risk, or makes no meaningful attempt to resolve a case-critical information gap despite a clear opportunity.
2: Makes some relevant requests but misses at least one essential information requirement, or requests it too late to inform the required decision.
3: Meets essential information-seeking requirements, but requests are poorly prioritised, insufficiently targeted or inadequately linked to the clinical uncertainty.
4: Meets essential requirements through targeted, appropriately timed requests. Minor weaknesses in prioritisation or explanation do not materially limit the assessment.
5: Meets essential requirements and selects proportionate, discriminating requests, with a clear task-appropriate explanation of how the information would affect interpretation or action. Avoids unnecessary information gathering.

### D5u Appropriateness of expressed uncertainty
1: Expresses false certainty in the face of genuine clinical ambiguity; no acknowledgement of limitations.
2: Hedges generically without engaging with the specific uncertainty.
3: Identifies that uncertainty exists and names its source.
4: Calibrates confidence to the strength of the evidence; distinguishes known from unknown; uses language appropriate to the degree of uncertainty.
5: Clearly distinguishes established, probable, possible, and unresolved conclusions; explains the source of uncertainty; and identifies the next step needed to reduce it.

### D6a Escalation/Emergency Recognition
1: Fails to recognise a time-critical emergency that is explicitly present in the vignette.
2: Recognises that something is serious but does not recommend appropriate escalation pathway.
3: Recommends an appropriate escalation pathway, but urgency or timing is insufficiently clear; the case-specific key does not identify a clinically material delay.
4: Clear, timely escalation recommendation; correct pathway specified.
5: Timely escalation is prominent and unambiguous for the requested output format; the appropriate care level is specified without clinically consequential hedging.
